Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com

Dow Jones

06/09

By George Glover

Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion.

Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65.

GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib.

The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years.

GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs.

Write to George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 09, 2026 10:00 ET (14:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2642493129"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642493129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642493129?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642493129","market":"nz","top_or_hot":-1,"title":"Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. \n</p>\n<p>\n  Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65. \n</p>\n<p>\n  GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib. \n</p>\n<p>\n  The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years. \n</p>\n<p>\n  GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-09 22:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. \n</p>\n<p>\n  Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65. \n</p>\n<p>\n  GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib. \n</p>\n<p>\n  The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years. \n</p>\n<p>\n  GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSKH","symbol_name":"GSK plc ADRhedged","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642493129","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642493129","pubTimestamp":1781013600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion.Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65.GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib.The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years.GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSKH":"GSK plc ADRhedged","BK4139":"生物科技","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","BK4007":"制药","BK4588":"碎股","NUVL":"Nuvalent, Inc.","GSK.UK":"葛兰素史克","BK4539":"次新股","BK4585":"ETF&股票定投概念"},"translate_title":"葛兰素史克(GSK)癌症药物意外交易导致Nuvalent股价上涨39%--Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"GSK":1.5,"NUVL":1.5,"GSK.UK":0.6},"content_text":"By George Glover \n\n\n  Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. \n\n\n  Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65. \n\n\n  GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib. \n\n\n  The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years. \n\n\n  GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs. \n\n\n  Write to George Glover at george.glover@dowjones.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 10:00 ET (14:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}